🇺🇸 FDA
Pipeline program

TAVR

AS-20170520

Phase 2 other active

Quick answer

TAVR for Aortic Valve Disease is a Phase 2 program (other) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Aortic Valve Disease
Phase
Phase 2
Modality
other
Status
active

Clinical trials